Cipla gets USFDA nod for generic cancer drug
NEW DELHI, Apr 11 (PTI): Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug.
The company has received the final approval from the US Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for paclitaxel protein-bound particles for injectable suspension (albumin-bound), 100 mg/vial, single-dose vial, Cipla said in a regulatory filing.
Cipla’s protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb’s Abraxane for injectable suspension 100 mg/vial.
